Podcast: CLL/SLL Guidelines

CE / CME

Current Clinical Practice and NCCN Guidelines for CLL/SLL

Physician Assistants: maximum of 0.50 hour of AAPA Category 1 CME credit

Registered Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: July 22, 2024

Expiration: July 21, 2025

Jeremy S. Abramson
Jeremy S. Abramson, MD, MMSc
Farrukh T. Awan
Farrukh T. Awan, MD, MS, MBA
Shuo Ma
Shuo Ma, MD, PhD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

An 82-yr-old woman was initially treated for CLL with bendamustine + rituximab, resulting in a 7-yr remission. She then develops symptomatic progression and is treated with venetoclax + rituximab for 2 yr, resulting in a 2-yr remission. She again requires treatment due to progressive lymphocytosis, cytopenia, and fatigue and receives zanubrutinib. She tolerates treatment well but experiences disease progression 3 yr later. FISH shows del(13q) and del(17p); NGS shows BTK C481 and BCL2 G101V mutations.

Which of the following would you recommend as the next best therapy for this 82-yr-old patient with CLL and multiple relapses?